Saoirse O’Sullivan
Vice President, Translational Sciences Artelo Biosciences
Prof. Saoirse Elizabeth O’Sullivan joined Artelo in October 2021 as Vice President, Translational Sciences, after having served several years as a scientific advisor to the Company. Dr. O’Sullivan received her doctorate from Trinity College Dublin in 2001 and moved to the University of Nottingham in 2002 as a Research fellow where she began researching cannabinoid pharmacology. She was made Lecturer in 2007, Associate Professor in 2011, and Professor in 2019. She has over 26 original research articles, 6 reviews and 3 books chapters on the topic of cannabinoid pharmacology, with specific interests on the cardiovascular and gastrointestinal effects of cannabinoids and therapeutic potential of cannabis-based medicines. Her research methodologies span from cellular and animal models to human healthy volunteer studies and early phase clinical trials. In 2016 she was named the International Cannabinoid Research Society Young Investigator of the Year.
Seminars
- Demonstrating semaglutide-like efficacy with once-daily oral, cannabinoid agonist ART27.13, achieving ~20% weight loss and significant fat mass reduction in a nonclinical obesity model
- Enhancing weight-loss outcomes through combination therapy, with ART27.13 and semaglutide together delivering ~40% weight loss, double that achieved by either treatment alone
- Unlocking a novel peripheral cannabinoid-based approach to metabolic regulation, improving body composition and metabolic health while showing obesity-specific effects
